EVALUATION THE INFLUENCE OF LIPOPROTEIN LIPASE GENE POLYMORPHISM ON ROSUVASTATIN TREATMENT OUTCOME IN PATIENTS WITH CORONARY ARTERY DISEASE IN AL NAJAF GOVERNORATE

Abstract

Background: Coronary artery disease is a heterogeneous, complex metabolic disorder characterized by elevated cholesterol and triglyceride concentrations called dyslipidemia, It is classified according to lipoprotein level and other further classes.

Aim of the study: To study the impact of Hind iii gene single nucleotides polymorphisms (rs 320) on Rosuvastatin response in coronary artery disease patients in Al-Najaf governorate.

Patients and Methods: The current prospective cohort study included 51 patients with coronary artery disease. The work with the study is dated back to December 2021 to September 2022. The study was carried out at internal medicine department in Al- Sader Teaching Hospital-Najaf- Iraq. The enrolled patients with coronary artery disease have been diagnosed by an cardiologist. The age ranged from 23 to 65 years.

The first blood sample was taken at time zero (time of diagnosis without treatment) and the second blood sample was taken after 8 weeks (after starting treatment) for each patient.

Results: The mean serum of triglyceride level, total cholesterol, VLDL-C, LDL-C, interleukin 6 level and mean body mass index (BMI) significantly reduced (p< 0.0001). while serum of HDL-C and lipoprotein lipase level significantly increased (p< 0.0001) after treatment with rosuvastatin. The LPL rs320 genotyping was: wild allele (TT), heterozygote variant (TG) and homozygote variant (GG).

Conclusions: In our research heterozygous variant most distributed then homozygous normal and the less distributed was homozygous variant. Rosuvastatin has been shown to be effective in improvement of serum lipid profile, lipoprotein lipase level and interleukin 6 level.